Compare · BURU vs TMO
BURU vs TMO
Side-by-side comparison of Nuburu Inc. (BURU) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- BURU operates in Miscellaneous, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $248.91B, about 26607.7x BURU ($9.4M).
- Over the past year, BURU is down 61.7% and TMO is up 28.0% - TMO leads by 89.7 points.
- TMO has been more active in the news (7 items in the past 4 weeks vs 6 for BURU).
- TMO has more recent analyst coverage (25 ratings vs 0 for BURU).
- Company
- Nuburu Inc.
- Thermo Fisher Scientific Inc
- Price
- $0.58-40.56%
- $686.99-1.37%
- Market cap
- $9.4M
- $248.91B
- 1M return
- -37.72%
- +4.36%
- 1Y return
- -61.72%
- +28.02%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 6
- 7
- Recent ratings
- 0
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest BURU
- SEC Form S-3 filed by Nuburu Inc.
- NUBURU Provides Update on Tekne Acquisition Timetable: Golden Power Approved, October 15 Closing Targeted
- SEC Form 8-K filed by Nuburu Inc.
- NUBURU Launches Site Dome Offering, Targets Major European Aerospace and Defense Manufacturer
- NUBURU Confirms Closing Funds in Place for Tekne Acquisition and Approximately $135.4 Million in Net Remaining Order Value
- Amendment: SEC Form 10-Q/A filed by Nuburu Inc.
- Nuburu Inc. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
- NUBURU Wins First 1W Laser Dazzler Pilot Order Advancing Its Law Enforcement and Public Security Offering
- NUBURU Announces Corrected CUSIP Number
- Nuburu Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Latest TMO
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- SEC Form 4 filed by Director Keith R. Alexandra
- Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
- Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
- Thermo Fisher upgraded by UBS with a new price target
- CLSA initiated coverage on Thermo Fisher with a new price target
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)